OrbiMed Launches $600 Million Fund to to Lure Life Science Companies Looking for Quick Cash
Published: Aug 31, 2011
OrbiMed has dedicated significant resources and personnel to support the new fund, including three OrbiMed Partners, Samuel D. Isaly, Sven H. Borho and W. Carter Neild, along with a dedicated team of four professionals: Tadd S. Wessel, Matthew S. Rizzo, Matthew L. Wotiz and J. Christopher LiPuma.
“Life sciences companies are typically dependent on equity markets to raise new capital,” observed Tadd Wessel, a Managing Director on the Royalty Opportunities team. “With this fund, OrbiMed can offer a minimally dilutive capital alternative to fund product launches, M&A opportunities, new product research, and general corporate purposes.”
“We welcome the opportunity to discuss with owners of royalty streams the potential to monetize those future cash flows in order to meet their financial objectives, from companies seeking to increase R&D, research institutions seeking new facilities, or individual inventors seeking liquidity,” noted Matthew Rizzo, also a Managing Director on the Royalty team.
OrbiMed’s Royalty team can be reached at (212) 739-6400.
OrbiMed Advisors LLC is a leading investment firm dedicated exclusively to the healthcare sector, with over $5 billion in assets under management. OrbiMed invests across the entire spectrum of healthcare companies on a worldwide basis. Investments are made through private equity funds, hedge funds, royalty funds, and other investment vehicles.
OrbiMed’s investment team includes over 50 experienced professionals with offices in New York City, San Francisco, Shanghai, Mumbai and Israel. As the largest investment firm solely dedicated to the healthcare sector, OrbiMed is a capital provider of choice, bringing the global resources required to be an exceptional long-term partner for building world-class healthcare companies. www.OrbiMed.com.
OrbiMed Advisors LLCW. Carter Neild, CFAPhone (212) 739.6469Email NeildC@OrbiMed.comwww.OrbiMed.com